跳转至内容
Merck

SML3155

Sigma-Aldrich

Brincidofovir

≥98% (HPLC)

别名:

3-(Hexadecyloxy)propyl hydrogen ((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yloxy)methylphosphonate, CMX 001, CMX001, Hexadecyloxypropyl-cidofovir

登录查看公司和协议定价

选择尺寸

5 MG
$119.00
25 MG
$478.00

$119.00


预计发货时间2025年5月22日详情


获取大包装报价

选择尺寸

变更视图
5 MG
$119.00
25 MG
$478.00

About This Item

经验公式(希尔记法):
C27H52N3O7P
分子量:
561.69
MDL號碼:
分類程式碼代碼:
51111800
分類程式碼代碼:
12352200
NACRES:
NA.77

$119.00


预计发货时间2025年5月22日详情


获取大包装报价

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear (Warmed)

儲存溫度

-10 to -25°C

SMILES 字串

[P](=O)(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@@H](CN1C=CC(=N)NC1=O)CO

InChI 密鑰

WXJFKKQWPMNTIM-VWLOTQADSA-N

生化/生理作用

Brincidofovir is an orally bioavailable prodrug of cidofovir with activity against pox viruses as well as CMV, HSV, and Varicella zoster.
Orally bioavailable prodrug of cidofovir with activity against pox viruses as well as CMV, HSV, and Varicella zoster

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Carc. 2 - Repr. 2 - Skin Sens. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Julio J Alvarez-Cardona et al.
Future microbiology, 15, 389-400 (2020-03-14)
Brincidofovir (BCV) is a lipid conjugate of cidofovir with good oral bioavailability, enabling optimal intracellular levels of the active drug. Lower rates of nephrotoxicity and myelotoxicity make it a favorable alternative. Despite a greater safety profile among pediatric hematopoietic cell transplant
Erik De Clercq
Medicinal research reviews, 33(6), 1249-1277 (2013-03-16)
Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed-dose combinations (FDCs), the most recent example being Stribild(TM); (ii) for hepatitis C virus (HCV), the pleiade of direct-acting antivirals (DAAs)
R Anthony Vere Hodge et al.
Advances in pharmacology (San Diego, Calif.), 67, 1-38 (2013-07-28)
This review starts with a brief description of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), the clinical diseases they cause, and the continuing clinical need for antiviral chemotherapy. A historical overview describes the progress from the early

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持